Methods for detecting Th1 cells
US-9175073-B2 · Nov 3, 2015 · US
US9453070B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9453070-B2 |
| Application number | US-201414528434-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 30, 2014 |
| Priority date | Apr 28, 2004 |
| Publication date | Sep 27, 2016 |
| Grant date | Sep 27, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.
Opening claim text (preview).
The invention claimed is: 1. A method of treating contact dermatitis in a human subject in need thereof, the method comprising administering to the human subject in need thereof a therapeutically effective amount of an antibody that specifically binds to a protein consisting of the amino acid sequence of SEQ ID NO:2, wherein the antibody binds to domain 1 (amino acids 27-136 of SEQ ID NO:2) and inhibits binding between the protein consisting of the amino acid sequence of SEQ ID NO:…
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.